Incretin-based therapy for diabetes prevention in patients with obesity In agreement with what has been previously shown for any weight-lowering lifestyle intervention and medication, regardless of their mechanism of action 18 , incretin-based AOM have been associated with amelioration of glucose metabolism and T2D prevention (Fig
HIGHLY RECOMMENDED Drugs: Compounded semaglutide and tirzepatide (both injectable and sublingual drops)
PMID 33598734
Lilly's TRIUMPH clinical program includes multiple Phase III trials evaluating retatrutide across different patient populations and endpoints: Seven additional Phase III readouts are expected throughout 2026, covering populations with type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and other obesity-related comorbidities Cardiovascular outcomes data the gold standard for demonstrating that weight loss translates into reduced heart attacks, strokes, and cardiovascular death will be critical for retatrutide's regulatory and commercial positioning Head-to-head trials comparing retatrutide directly to existing therapies may provide definitive comparative efficacy data The Drug vs
Broad, clearly described supporting formula
These drugs are engineered to remain in the body for days, unlike the naturally occurring hormone, which breaks down in just minutes